Bolivia Certificate of Free Sale: Legalisation and the Two-Year Acceptance Rule
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Bolivia requires the Certificate of Free Sale (Certificado de Libre Venta) to be issued or endorsed by the national health authority of the country of origin and to complete consular legalization by a Bolivian consulate; where no Bolivian consulate exists in the country of origin, the original document is submitted together with authentication by the Bolivian Ministry of Foreign Affairs. If the certificate does not state a validity period, it is accepted for 2 years from the date of issue under Section 2.3.2 of the Manual. GRZAN’s practical observation is that this is the most common bottleneck encountered by Chinese companies entering Bolivia: the sequence matters, and companies should first confirm whether the competent authority of the country of origin can issue or endorse the certificate, and only then schedule the project. If this confirmation is skipped, the entire project can stall at the very first documentary step, because registration cannot proceed without a properly legalized free sale document. The timing risk is compounded by the legalization chain itself: issuance, consular or apostille legalization and translation each consume calendar time, and none of these steps can be compressed once the dossier submission date has been fixed. The same confirmation discipline applies to translations and notarization, which are frequently required downstream of the certificate itself.
2. Legal basis
| Regulation | Reference number | Publication date | Provision |
|---|---|---|---|
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | Current version as published on the AGEMED website | Section 2.3.2 |
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | Current version as published on the AGEMED website | Section 2.4.7 |
| Hague Convention Abolishing the Requirement of Legalisation for Foreign Public Documents | Apostille Convention | Bolivia: May 7, 2018 | Entire text |
| Decreto Supremo (implementing regulation of the medicines law) | Decreto Supremo N° 25235 | November 30, 1998 | Article 42 |
3. Expert insights
Insight one: the 2-year rule is an acceptance standard, not a validity period. Section 2.3.2 provides that a certificate which does not state its own validity is accepted for 2 years after issuance. This means that, in practice, the newer the certificate, the better, and the acceptance window is not synchronized with the re-registration cycle, which runs for 5 years. A certificate issued at first registration will normally have aged out of the acceptance window by the time re-registration falls due, so companies must obtain a new certificate when re-registering. The new document should be commissioned as soon as the renewal timeline is known, since issuance plus legalization can take weeks. Planning certificate issuance as a recurring activity aligned to each filing, rather than as a one-time task, prevents unpleasant surprises during renewal. A practical habit is to schedule certificate issuance against the submission calendar of each filing, so that the document is generated at the moment it is needed and never stored to age in a drawer.
Insight two: whether an apostille can replace consular legalization must be confirmed with AGEMED. Bolivia has been a member of the Hague Apostille Convention since May 7, 2018, so in principle an apostille can replace the consular legalization chain. However, the text of the Manual predates that date, and its provisions still describe the consular route as the default. GRZAN’s recommendation is therefore to prepare the apostille route while simultaneously confirming the current accepted practice with AGEMED in writing, rather than making a unilateral assumption. This dual-track approach costs little and avoids the scenario in which a legalized document is rejected at intake because the reviewer follows the literal text of the Manual. Where the confirmation is obtained, keep it in the project file, because it documents that the chosen legalization route reflects the current position of the authority.
Insight three: the certificate of free sale is the carrier of the risk classification. Section 2.4.7 provides that if the certificate does not state the device’s risk level, the level declared by the manufacturer is filled in. This makes the certificate more than an administrative formality: it can either corroborate or weaken the classification position taken in the dossier. Obtaining a certificate that states the risk level reduces dependence on the self-declared figure and removes one potential source of classification disputes during review. Where the issuing authority refuses to state a level, companies should keep the classification rationale in the technical file well documented to support the declared figure. The comparison between the certificate and the classification section of the dossier should be made before submission, not after.
4. Practical recommendations
- Make the first task of project initiation a confirmation of whether the competent authority of the country of origin can issue or endorse the certificate of free sale, including the expected lead time and any document prerequisites, before committing to a submission date.
- Seek to have the product risk level stated in the certificate, which reduces the scope for later classification disputes and strengthens the dossier’s internal consistency.
- Work backwards from the 2-year acceptance standard when scheduling issuance, so that the certificate is at its freshest at the moment of submission and remains within the acceptance window through any review exchanges.
- Confirm the legalization route with AGEMED in writing before choosing between the apostille and consular pathways, and keep the confirmation in the project file.
5. Verification checklist
- □ The competent authority of the country of origin can issue or endorse the certificate of free sale
- □ The certificate states a validity period; if not, it falls within 2 years of issue
- □ The certificate states the product risk level
- □ The legalization method, apostille or consular legalization, has been confirmed with AGEMED
- □ Where no Bolivian consulate exists, the Ministry of Foreign Affairs authentication route has been confirmed
Regulatory information verified as of October 29, 2026.
GRZAN provides registration support in Bolivia for manufacturers, importers and authorized representatives, covering free sale certificate strategy, legalization coordination, dossier preparation and regulatory correspondence. For assistance with certificates of free sale and the full registration process, contact info@grzanglobal.com. Support includes scheduling certificate issuance against each submission and confirming the legalization route with the authority.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us